JP2009517009A - エリスロポエチンポリペプチド及びそれらの使用 - Google Patents

エリスロポエチンポリペプチド及びそれらの使用 Download PDF

Info

Publication number
JP2009517009A
JP2009517009A JP2008541750A JP2008541750A JP2009517009A JP 2009517009 A JP2009517009 A JP 2009517009A JP 2008541750 A JP2008541750 A JP 2008541750A JP 2008541750 A JP2008541750 A JP 2008541750A JP 2009517009 A JP2009517009 A JP 2009517009A
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
amino acids
epo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008541750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517009A5 (https=
Inventor
アブデルラヒーム、ハーディ
プリマス、グエナエル
クヴァトクコ、ヨランドゥ
マウンドレル、キンゼー
Original Assignee
ラボラトワ セローノ エス．エイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラボラトワ セローノ エス．エイ． filed Critical ラボラトワ セローノ エス．エイ．
Publication of JP2009517009A publication Critical patent/JP2009517009A/ja
Publication of JP2009517009A5 publication Critical patent/JP2009517009A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2008541750A 2005-11-24 2006-11-23 エリスロポエチンポリペプチド及びそれらの使用 Pending JP2009517009A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05111262 2005-11-24
EP05111265 2005-11-24
US75370605P 2005-12-22 2005-12-22
US75366805P 2005-12-22 2005-12-22
PCT/EP2006/068859 WO2007060213A2 (en) 2005-11-24 2006-11-23 Erythropoietin polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2009517009A true JP2009517009A (ja) 2009-04-30
JP2009517009A5 JP2009517009A5 (https=) 2010-02-04

Family

ID=37807876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008541750A Pending JP2009517009A (ja) 2005-11-24 2006-11-23 エリスロポエチンポリペプチド及びそれらの使用

Country Status (7)

Country Link
US (1) US20080260746A1 (https=)
EP (1) EP1966237A2 (https=)
JP (1) JP2009517009A (https=)
AU (1) AU2006316450A1 (https=)
CA (1) CA2621705A1 (https=)
IL (1) IL191426A (https=)
WO (1) WO2007060213A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715479A4 (en) * 2004-02-09 2008-09-03 Pioneer Design Corp OPTICAL ELEMENT, OPTICAL BUYER AND INFORMATION RECORDING / REPRODUCING DEVICE
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
WO2008074851A2 (en) * 2006-12-19 2008-06-26 Nokad Method for inhibiting the expression of endogenous erythropoietin (epo)
WO2008151841A2 (en) * 2007-06-15 2008-12-18 University Of Zurich Treatment for alzheimer' s disease
BRPI0814465B1 (pt) 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
WO2012097256A1 (en) * 2011-01-14 2012-07-19 University Of Tennessee Research Foundation Therapeutic compositions and methods for disorders associated with neuronal degeneration
CN102816853A (zh) * 2012-08-30 2012-12-12 山东百福基因科技有限公司 运动机能相关基因epo荧光检测试剂盒及检测方法
DK2928921T3 (da) 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
US20210340241A1 (en) * 2014-06-12 2021-11-04 Andremacon S.R.L. Use of negative functional modulators of erythropoietin for therapy
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
CN110475786A (zh) * 2017-02-27 2019-11-19 大邱庆北科学技术院 红细胞生成素衍生肽通过其对预防细胞损伤的作用的用途
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500558A (ja) * 1983-02-04 1985-04-25 キリン−アムジェン、インコ−ポレ−テッド Ａｔｃｃ　ｈｂ８２０９　及びそのエリスロポエチンに対するモノクロ−ナル抗体
JPH10101574A (ja) * 1996-08-06 1998-04-21 Snow Brand Milk Prod Co Ltd 増殖性臓器疾患治療・改善剤
WO2004003176A2 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
AU721196B2 (en) * 1996-10-25 2000-06-29 G.D. Searle & Co. Circularly permuted erythropoietin receptor agonists
US7033774B2 (en) * 1997-04-21 2006-04-25 Glycozyme, Inc. Determination of recombinant glycosylated proteins and peptides in biological fluids
US20040229779A1 (en) * 1999-05-14 2004-11-18 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6974684B2 (en) * 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
AU2003304034A1 (en) * 2002-08-09 2004-11-01 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7846466B2 (en) * 2004-06-10 2010-12-07 Northwestern University Biodegradable scaffolds and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500558A (ja) * 1983-02-04 1985-04-25 キリン−アムジェン、インコ−ポレ−テッド Ａｔｃｃ　ｈｂ８２０９　及びそのエリスロポエチンに対するモノクロ−ナル抗体
JPH10101574A (ja) * 1996-08-06 1998-04-21 Snow Brand Milk Prod Co Ltd 増殖性臓器疾患治療・改善剤
WO2004003176A2 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012011068; Ｓｃｉｅｎｃｅ　（２００４）　ｖｏｌ．３０５，　ｎｏ．５６８１，　ｐ．２３９-２４２ *
JPN6012011069; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ．　（１９９３）　ｖｏｌ．２６８，　ｎｏ．２１，　ｐ．１５９８３-１５９９３ *
JPN6012011070; Ｎａｔ．　Ｒｅｖ．　Ｎｅｕｒｏｓｃｉ．　（Ｊｕｎ　２００５）　ｖｏｌ．６，　ｎｏ．６，　ｐ．４８４-４９４ *

Also Published As

Publication number Publication date
WO2007060213A3 (en) 2008-08-14
WO2007060213A2 (en) 2007-05-31
AU2006316450A1 (en) 2007-05-31
CA2621705A1 (en) 2007-05-31
IL191426A (en) 2012-05-31
US20080260746A1 (en) 2008-10-23
EP1966237A2 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
JP5858442B2 (ja) Ｒｏｂｏ１−Ｆｃ融合タンパク質および腫瘍を治療するためのこの使用
KR101626153B1 (ko) 조직 보호 펩티드 및 이의 용도
IL191426A (en) Erythropoietin polypeptides, their preparation and uses thereof
JP2021175755A (ja) 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
JP2010248207A (ja) 貧血の予防および治療用の方法および組成物
JP2003530874A (ja) 貧血の予防及び治療用の方法及び組成物
JP2012530493A (ja) キメラポリペプチドおよびその使用
BRPI1011404B1 (pt) Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
JPH10113186A (ja) トロンボポエチンをコードする遺伝子
JP2012525847A (ja) Ｆｇｆ２１変異体およびその使用
BR122020010972B1 (pt) polipeptídeo isolado e de fusão, sua composição farmacêutica e multímero
JP2016521688A (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
NZ543192A (en) Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
EP2655408B1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
US20190106470A1 (en) Erythropoietin variants
EP1885747B1 (en) Erythropoietin variants
JP2002543784A (ja) 新規なチンパンジーエリスロポエチン（ｃｈｅｐｏ）ポリペプチドおよびこれをコードする核酸
JPH04506513A (ja) 巨核球増殖促進活性
KR20010043090A (ko) 신규인 폴리펩티드, 그 폴리펩티드를 코드화하는 ｃＤＮＡ및 그 용도
JP2003511030A (ja) 成長因子ポリペプチドおよび成長因子ポリペプチドをコードする核酸
JP2010540660A (ja) 哺乳類内の赤血球生成を刺激する新規の組成物および方法
HUT75656A (en) Protein having tpo activity
JP2002335972A (ja) インスリン受容体関連受容体結合蛋白質及びその利用
US20020192704A1 (en) Insulin receptor-related receptor binding protein and utilization of the same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120518

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120702

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130419